Next-Generation Sequencing in Cancer Care

News
Article

Cancer teams can decode and analyze DNA from a patient’s tumor to diagnose the disease, determine personalized treatment plans and assess the response to treatment.

Next-generation sequencing (NGS), also known as high-throughput sequencing, is a technology used to decode and analyze DNA or RNA. It has emerged as a transformative tool in cancer care, revolutionizing how doctors understand, diagnose and manage the disease.

With NGS, cancer teams are able to analyze the genetic information of tumor cells via a tissue biopsy or liquid biopsy (from blood, urine or another body fluid). Once sequenced and analyzed, this information can be used in several ways throughout a patient’s cancer journey.

Diagnosis and Classification

NGS plays a crucial role in identifying and classifying different types of cancer. By analyzing the genetic material within a patient’s tumor, NGS helps doctors pinpoint the specific genetic mutations or alterations that are driving the cancer’s growth. This information is vital in determining the exact type of cancer a patient has, which guides treatment decisions.

Personalized Treatment Plans

Cancer is a highly heterogeneous disease, meaning it can differ greatly from person to person. NGS enables doctors to create personalized treatment plans tailored to the genetic makeup of each patient’s tumor. This precision medicine approach allows for the selection of targeted therapies that are more likely to be effective against the specific genetic abnormalities present in the cancer cells.

Targeted Therapy Selection

NGS identifies genetic mutations that can be targeted with specific drugs. For instance, if a patient’s tumor has a mutation that makes it susceptible to a particular targeted therapy, NGS can guide doctors in choosing that treatment. This approach minimizes trial and error, increasing the chances of a successful response while reducing unnecessary side effects.

Monitoring Treatment Response

During the course of treatment, NGS can be used to monitor the tumor’s genetic changes. If new mutations or alterations emerge, doctors can adjust the treatment plan accordingly. This real-time monitoring helps ensure that the chosen therapy remains effective and provides insights into any potential drug resistance.

Predicting Disease Progression

NGS can provide insights into the likelihood of a patient’s cancer spreading or recurring. By analyzing specific genetic markers, doctors can better predict the course of the disease and make informed decisions about long-term treatment strategies.

Research and Clinical Trials

NGS contributes to cancer research by providing a wealth of genetic data that scientists can analyze to uncover new insights into the disease’s mechanisms. Additionally, patients with cancer may have the opportunity to participate in clinical trials for experimental treatments based on their genetic profile, potentially expanding their access to cutting-edge therapies.

Early Detection and Risk Assessment

NGS can also be employed for early detection and risk assessment. By analyzing a patient’s genetic predisposition, doctors can identify individuals who are at higher risk of developing certain types of cancer. This knowledge allows for enhanced surveillance and preventive measures.

Hereditary Cancer Syndromes

In cases where cancer seems to run in families, NGS can be used to identify hereditary cancer syndromes caused by specific gene mutations. This information helps guide not only the patient’s treatment but also the screening and management of family members who may be at risk.

In essence, NGS is a powerful tool that empowers patients with personalized, targeted and informed cancer care. It opens new avenues for treatment, enhances treatment effectiveness and contributes to the ongoing advancement of cancer research and treatment options.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Related Content